JMP maintains Market Perform on Globus Medical stock

Globus Medical (GMED) reported weaker-than-expected Q1 2025 revenue and earnings due to lower Enabling Technology sales and supply chain issues related to the NuVasive merger, though these issues were resolved by quarter's end. Despite the shortfall, core business fundamentals remain strong, with analysts noting robust demand for the Enabling Tech segment and a "GREAT" overall financial health score, further evidenced by record Q1 free cash flow and the repayment of all merger-related debt, leaving the company debt-free. GMED has also launched a $500 million share repurchase program, but analyst price targets have been adjusted downward due to concerns over the Nevro Corp. integration, which is expected to be more dilutive to earnings.

Analysis

Globus Medical (GMED) reported a challenging first quarter for 2025, with revenue of $598.1 million falling short of the anticipated $626 million to $630.1 million range, and earnings also missing expectations. This underperformance was primarily attributed to lower-than-expected sales in its Enabling Technology segment and supply chain disruptions stemming from the integration of legacy NuVasive products; however, these supply chain issues were reportedly resolved by the end of the quarter. Despite these setbacks, the company's core business fundamentals are described as robust, with continued strong demand for its Enabling Technology. Financially, Globus Medical achieved a record level of free cash flow for a first quarter and successfully repaid all outstanding debt associated with the NuVasive merger, resulting in a debt-free balance sheet. The company's last twelve months' revenue grew by 32%, accompanied by a gross profit margin of 67%, and it maintains a strong liquidity position evidenced by a current ratio of 4.45. In response to perceived undervaluation, GMED launched a $500 million share repurchase program. Nevertheless, several analyst firms, including Oppenheimer, Truist Securities, BTIG, and Stifel, have adjusted their price targets downwards, reflecting concerns over the Q1 miss and the potentially greater-than-anticipated earnings dilution from the Nevro Corp. acquisition. While Globus Medical has maintained its full-year revenue guidance for 2025, its earnings per share forecast has been slightly reduced. JMP analysts maintained their Market Perform rating, reflecting a cautious but stable outlook amidst these mixed signals.

Key Decisions for Investors

• Investors should weigh the Q1 2025 revenue and earnings miss, alongside concerns about Nevro Corp. integration diluting earnings, against the company's now debt-free balance sheet, record Q1 free cash flow, and resolved supply chain issues.
• Closely monitor the progress of NuVasive and Nevro integrations, the recovery and growth trajectory of Enabling Technology sales, and the company's ability to meet its revised earnings per share forecast for 2025.
• Consider the $500 million share repurchase program as a potential positive catalyst and a signal of management's confidence in the company's valuation, though its market impact will be contingent on execution and prevailing conditions.
• A cautious approach may be warranted, aligning with the 'Market Perform' consensus, pending further evidence of sustained operational improvements and successful synergy realization from recent acquisitions.